内視鏡的逆行性胆管膵管造影/ERCPの世界市場予測(~2026):製品別、処置別、エンドユーザー別

◆英語タイトル:Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) - Global Forecast to 2026

MarketsandMarketsが発行した調査報告書(MD 8059-22)◆商品コード:MD 8059-22
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2022年3月16日
◆ページ数:231
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社は、世界の内視鏡的逆行性胆管膵管造影/ERCP市場規模が2021年13億ドルから2026年20億ドルまで、年平均9.6%成長すると予想しています。本市場調査資料では、内視鏡的逆行性胆管膵管造影/ERCPの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業インサイト、製品別(内視鏡、内視鏡装置、可視化システム、エネルギー装置、その他)分析、処置別(胆管括約筋、胆管拡張、胆管ステント留置、膵臓括約筋、膵管拡張)分析、エンドユーザー別(病院、外来手術センター/クリニック、その他)分析、地域別分析、競争状況、企業情報などを整理しました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業インサイト
・世界の内視鏡的逆行性胆管膵管造影/ERCP市場規模:製品別(内視鏡、内視鏡装置、可視化システム、エネルギー装置、その他)
・世界の内視鏡的逆行性胆管膵管造影/ERCP市場規模:処置別(胆管括約筋、胆管拡張、胆管ステント留置、膵臓括約筋、膵管拡張)
・世界の内視鏡的逆行性胆管膵管造影/ERCP市場規模:エンドユーザー別(病院、外来手術センター/クリニック、その他)
・世界の内視鏡的逆行性胆管膵管造影/ERCP市場規模:地域別
・競争状況
・企業情報

“The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3 billion in 2021, at a CAGR of 9.6% during the forecast period.”
The growth of this market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries. On the other hand, the high costs of endoscopic retrograde cholangiopancreatography devices, the development of other procedures like EUS and MRCP, and the shortage of trained physicians and endoscopists are factors expected to restrain the market growth to a certain extent.

“The endotherapy devices segment accounted for the largest share of the endoscopic retrograde cholangiopancreatography market in 2020.”
Based on products, the endoscopic retrograde cholangiopancreatography market has been segmented into endoscopes, endotherapy devices, visualization systems, energy devices, and others. The factors attributing to the large revenue of the endotherapy devices segment include the growing preference for minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.

“The markets in Asia Pacific and Latin America is projected to witness the highest growth rate during the forecast period (2021–2026).”
North America accounted for the largest share of the Endoscopic retrograde cholangiopancreatography market in 2020. The increasing prevalence of cancer, high investments by hospitals to purchase new ERCP equipment, and a strong focus on research activities to improve endoscopy techniques are the major factor contributing to this.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type (Supply-side): Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%
• By Designation: C-level: 43%, Director-level: 32%, and Others: 25%
• By Region: North America: 38%, Europe: 23%, Asia-Pacific: 29%, Latin America: 5%, and Middle East & Africa: 5%

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).
Other players in the market include Hobbs Medical, Inc. (US), STERIS PLC (US), Merit Medical Systems, Inc. (US), TeleMed Systems, Inc. (US), Changzhou Health Microport Medical Device Co., LTD. (China), Medi-Globe GmbH (Germany), Taewoong Medical Co., Ltd. (South Korea), Huger Medical Instrument Co., Ltd. (China), IntroMedic Co., Ltd. (Republic of Korea), SonoScape Medical Corporation (China), Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China), Ottomed (India), Kimberly-Clark Corporation (US), and Shaili Endoscopy (India).

Research Coverage:
The report analyzes the endoscopic retrograde cholangiopancreatography market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the endoscopic retrograde cholangiopancreatography market. The report analyzes the market based on the products and region.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the endoscopic retrograde cholangiopancreatography market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of endoscopic retrograde cholangiopancreatography solutions across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the endoscopic retrograde cholangiopancreatography market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the endoscopic retrograde cholangiopancreatography markets.

❖ レポートの目次 ❖

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
FIGURE 1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 31
1.3.2 YEARS CONSIDERED 31
1.4 CURRENCY 32
1.5 LIMITATIONS 32
1.6 STAKEHOLDERS 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 2 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 36
FIGURE 3 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET) 38
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 39
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 40
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION 40
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2020) 41
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026) 42
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43
FIGURE 11 TOP-DOWN APPROACH 44
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
FIGURE 12 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ESTIMATION 45
2.5 STUDY ASSUMPTIONS 45
2.6 LIMITATIONS 46
2.6.1 METHODOLOGY-RELATED LIMITATIONS 46
2.7 RISK ASSESSMENT 46
2.8 ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 47
3 EXECUTIVE SUMMARY 48
FIGURE 13 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION) 48
FIGURE 14 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION) 49
FIGURE 15 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 49
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 50
4 PREMIUM INSIGHTS 51
4.1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW 51
FIGURE 17 INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH 51
4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 52
FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET DURING THE FORECAST PERIOD 52
4.3 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT AND COUNTRY (2020) 53
FIGURE 19 THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020 53
4.4 REGIONAL MIX: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026) 54
FIGURE 20 THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026) 54
4.5 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: DEVELOPED VS. DEVELOPING MARKETS 54
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 56
FIGURE 22 MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 56
5.2.1 MARKET DRIVERS 56
5.2.1.1 Rising incidence of cancer 56
FIGURE 23 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020 57
5.2.1.2 Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research 57
TABLE 1 MAJOR DEVELOPMENTS 57
5.2.1.3 Growing focus on investments by hospitals for advanced endoscopy instruments 58
TABLE 2 SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS 58
5.2.1.4 Increasing preference for minimally invasive surgeries 59
FIGURE 24 ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030) 59
5.2.2 MARKET RESTRAINTS 59
5.2.2.1 High costs of endoscopic retrograde cholangiopancreatography devices 59
5.2.2.2 Development of other procedures like EUS and MRCP 60
5.2.2.3 Shortage of trained physicians and endoscopists 60
5.2.3 MARKET OPPORTUNITIES 60
5.2.3.1 The growing healthcare sector in emerging economies 60
5.2.3.2 Increasing adoption of single-use endoscopy instruments 61
5.2.4 MARKET CHALLENGES 61
5.2.4.1 Product recalls witnessed by major market players 61
TABLE 3 LIST OF PRODUCT RECALLS 61
5.2.4.2 Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products 62
6 INDUSTRY INSIGHTS 63
6.1 INTRODUCTION 63
6.2 TECHNOLOGY TRENDS 63
6.2.1 ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY 63
TABLE 4 AI SYSTEMS AND OTHER RELATED FUNCTIONS 63
6.2.2 SINGLE-USE ENDOSCOPES 64
TABLE 5 ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES 64
6.2.3 ROBOT-ASSISTED ENDOSCOPES 65
TABLE 6 ROBOT-ASSISTED ENDOSCOPY PRODUCTS 66
6.3 INDUSTRY TRENDS 66
6.3.1 FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES 66
6.4 PRICING ANALYSIS 66
TABLE 7 AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD) 66
TABLE 8 US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD) 67
6.5 VALUE CHAIN ANALYSIS 68
FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE 68
6.6 ECOSYSTEM MAPPING 69
FIGURE 26 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: ECOSYSTEM ANALYSIS 69
6.7 SUPPLY CHAIN ANALYSIS 70
FIGURE 27 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: STAKEHOLDERS IN SUPPLY CHAIN 71
6.8 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS 71
6.8.1 THREAT OF NEW ENTRANTS 72
6.8.1.1 High capital requirement 72
6.8.1.2 High preference for products from well-established brands 72
6.8.2 THREAT OF SUBSTITUTES 72
6.8.2.1 Substitute therapies for ERCP procedures 72
6.8.3 BARGAINING POWER OF SUPPLIERS 72
6.8.3.1 Presence of several raw material suppliers 72
6.8.3.2 Supplier switching costs 72
6.8.4 BARGAINING POWER OF BUYERS 72
6.8.4.1 Few companies offer premium products at the global level 72
6.8.5 INTENSITY OF COMPETITIVE RIVALRY 73
6.8.5.1 Increasing demand for high-quality and innovative products 73
6.8.5.2 Lucrative growth potential in emerging markets 73
6.9 REGULATORY ANALYSIS 73
6.10 PATENT ANALYSIS 74
6.10.1 PATENT PUBLICATION TRENDS FOR ERCP 74
FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021 74
6.10.2 TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS 75
FIGURE 29 TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021 75
6.10.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 75
FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021 75
6.11 TRADE ANALYSIS 76
TABLE 10 NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT 76
6.12 IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET 77
7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT 78
7.1 INTRODUCTION 79
TABLE 11 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 79
7.2 ENDOSCOPES 79
7.2.1 THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET 79
TABLE 12 ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 80
7.3 ENDOTHERAPY DEVICES 81
7.3.1 THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS 81
TABLE 13 ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 81
TABLE 14 ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 82
7.3.2 SPHINCTEROTOME 82
7.3.2.1 The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality 82
TABLE 15 SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
7.3.3 LITHOTRIPTER 83
7.3.3.1 Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally 83
TABLE 16 LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
7.3.4 STENTS 84
7.3.4.1 Metal stents have higher patency rates and are less expensive than plastic stents 84
TABLE 17 STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
7.3.5 CANNULAS 85
7.3.5.1 The success rate of ERCP procedures is directly proportional to cannulation 85
TABLE 18 CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
7.3.6 FORCEPS 86
7.3.6.1 The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples 86
TABLE 19 FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 87
7.3.7 SNARES 87
7.3.7.1 Snares are commonly used for cold or hot polypectomy 87
TABLE 20 SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88
7.3.8 CATHETERS 88
7.3.8.1 Catheters inject a contrast medium for the visualization of internal tissues 88
TABLE 21 CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89
7.3.9 GUIDING WIRES 89
7.3.9.1 The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches 89
TABLE 22 GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
7.3.10 BALLOONS 90
7.3.10.1 Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract 90
TABLE 23 BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 91
7.3.11 BASKETS 91
7.3.11.1 Baskets are commonly used instruments for the removal of bile duct stones in ERCP 91
TABLE 24 BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
7.4 VISUALIZATION SYSTEMS 92
7.4.1 VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES 92
TABLE 25 VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.5 ENERGY DEVICES 93
7.5.1 ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR 93
TABLE 26 ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.6 OTHERS 94
TABLE 27 ERCP ACCESSORIES AND DESCRIPTIONS 94
TABLE 28 OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
8 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE 96
8.1 INTRODUCTION 97
TABLE 29 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 97
8.2 BILIARY SPHINCTEROTOMY 97
8.2.1 INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT 97
TABLE 30 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION) 98
8.3 BILIARY DILATATION 98
8.3.1 HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES 98
TABLE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION) 99
8.4 BILIARY STENTING 99
8.4.1 THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS 99
TABLE 32 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION) 100
8.5 PANCREATIC SPHINCTEROTOMY 100
8.5.1 THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE 100
TABLE 33 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION) 101
8.6 PANCREATIC DUCT DILATATION 101
8.6.1 BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL 101
TABLE 34 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION) 102
8.7 PANCREATIC DUCT STENTING 102
8.7.1 PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS 102
TABLE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION) 103
9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 105
9.2 HOSPITALS 105
9.2.1 INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT 105
TABLE 37 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION) 106
9.3 AMBULATORY SURGERY CENTERS/CLINICS 106
9.3.1 AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ECRP PROCEDURES THROUGH EFFICIENT OPERATIONS 106
TABLE 38 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION) 107
9.4 OTHER END USERS 107
TABLE 39 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 108
10 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION 109
10.1 INTRODUCTION 110
FIGURE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 110
TABLE 40 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION, 2019–2026 (USD MILLION) 111
10.2 NORTH AMERICA 111
FIGURE 32 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT 112
TABLE 41 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 112
TABLE 42 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 113
TABLE 43 NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 113
TABLE 44 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 114
TABLE 45 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER,
2019–2026 (USD MILLION) 114
10.2.1 US 114
10.2.1.1 The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer 114
TABLE 46 MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020 115
TABLE 47 LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021 116
TABLE 48 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 116
TABLE 49 US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 50 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 117
TABLE 51 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 118
10.2.2 CANADA 118
10.2.2.1 High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada 118
TABLE 52 INCIDENCE ESTIMATES BY CANCER TYPE (CANADA) 118
TABLE 53 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 119
TABLE 54 CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 55 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 120
TABLE 56 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 121
10.3 EUROPE 121
TABLE 57 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 58 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 122
TABLE 59 EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 122
TABLE 60 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 123
TABLE 61 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 123
10.3.1 GERMANY 123
10.3.1.1 Germany’s rising geriatric population is one of the key drivers for the ERCP market 123
TABLE 62 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 124
TABLE 63 GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 64 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 125
TABLE 65 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 126
10.3.2 UK 126
10.3.2.1 Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK 126
TABLE 66 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 127
TABLE 67 UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 68 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 128
TABLE 69 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 128
10.3.3 FRANCE 128
10.3.3.1 High healthcare expenditure is expected to support the growth of the ERCP market in France 128
TABLE 70 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 129
TABLE 71 FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 129
TABLE 72 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 130
TABLE 73 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 130
10.3.4 SPAIN 130
10.3.4.1 Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes 130
TABLE 74 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 131
TABLE 75 SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 76 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 132
TABLE 77 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 132
10.3.5 ITALY 132
10.3.5.1 Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy 132
TABLE 78 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 133
TABLE 79 ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 133
TABLE 80 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 134
TABLE 81 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 134
10.3.6 REST OF EUROPE (ROE) 134
TABLE 82 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 135
TABLE 83 ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 84 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 136
TABLE 85 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 136
10.4 ASIA PACIFIC 136
FIGURE 33 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT 137
TABLE 86 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 87 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 138
TABLE 88 ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 89 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 139
TABLE 90 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 140
10.4.1 JAPAN 140
10.4.1.1 Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan 140
TABLE 91 JAPAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 141
TABLE 92 JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 93 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 142
TABLE 94 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 142
10.4.2 CHINA 142
10.4.2.1 Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China 142
TABLE 95 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 143
TABLE 96 CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 143
TABLE 97 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 144
TABLE 98 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 144
10.4.3 INDIA 144
10.4.3.1 Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India 144
TABLE 99 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 145
TABLE 100 INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 145
TABLE 101 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 146
TABLE 102 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 146
10.4.4 AUSTRALIA 146
10.4.4.1 The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments 146
TABLE 103 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 147
TABLE 104 AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 105 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 148
TABLE 106 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 148
10.4.5 REST OF ASIA PACIFIC (ROAPAC) 148
TABLE 107 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 149
TABLE 108 ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 149
TABLE 109 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 150
TABLE 110 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 150
10.5 LATIN AMERICA 150
10.5.1 THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE 150
TABLE 111 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 151
TABLE 112 LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 152
TABLE 113 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 152
TABLE 114 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER,
2019–2026 (USD MILLION) 153
10.5.2 MIDDLE EAST 153
10.5.2.1 Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region 153
TABLE 115 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 153
TABLE 116 MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 117 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 154
TABLE 118 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 155
10.5.3 AFRICA 155
10.5.3.1 High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth 155
TABLE 119 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 156
TABLE 120 AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 121 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 157
TABLE 122 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION) 157
11 COMPETITIVE LANDSCAPE 158
11.1 OVERVIEW 158
11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN 158
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 158
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 160
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 160
11.4 COMPETITIVE BENCHMARKING 161
TABLE 123 FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET 161
TABLE 124 PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES) 162
TABLE 125 END USER: COMPANY FOOTPRINT (25 COMPANIES) 163
TABLE 126 REGION: COMPANY FOOTPRINT (26 COMPANIES) 164
11.5 COMPETITIVE LEADERSHIP MAPPING 165
11.5.1 STAR 165
11.5.2 EMERGING LEADER 165
11.5.3 PERVASIVE PLAYER 166
11.5.4 PARTICIPANT 166
FIGURE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 166
11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES 167
11.6.1 PROGRESSIVE COMPANY 167
11.6.2 DYNAMIC COMPANY 167
11.6.3 STARTING BLOCK 167
11.6.4 RESPONSIVE COMPANY 167
FIGURE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020) 168
11.7 MARKET RANKING ANALYSIS 168
FIGURE 37 ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020 169
FIGURE 38 ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER, 2020 170
11.8 COMPETITIVE SCENARIO 170
TABLE 127 PRODUCT LAUNCHES & APPROVALS, 2019–2021 170
TABLE 128 DEALS, 2019–2021 171
12 COMPANY PROFILES 173
(Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made)*
12.1 KEY PLAYERS 173
12.1.1 OLYMPUS CORPORATION 173
TABLE 129 OLYMPUS CORPORATION: BUSINESS OVERVIEW 173
FIGURE 39 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020) 174
12.1.2 CONMED CORPORATION 178
TABLE 130 CONMED CORPORATION: BUSINESS OVERVIEW 178
FIGURE 40 COMPANY SNAPSHOT: CONMED CORPORATION (2020) 179
12.1.3 AMBU A/S 181
TABLE 131 AMBU A/S: BUSINESS OVERVIEW 181
FIGURE 41 COMPANY SNAPSHOT: AMBU A/S (2020) 182
12.1.4 BOSTON SCIENTIFIC CORPORATION 184
TABLE 132 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 184
FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020) 185
12.1.5 JOHNSON & JOHNSON 189
TABLE 133 JOHNSON & JOHNSON: BUSINESS OVERVIEW 189
FIGURE 43 COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020) 190
12.1.6 FUJIFILM HOLDINGS CORPORATION 193
TABLE 134 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 193
FIGURE 44 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020) 194
12.1.7 MEDTRONIC, PLC 197
TABLE 135 MEDTRONIC, PLC: BUSINESS OVERVIEW 197
FIGURE 45 COMPANY SNAPSHOT: MEDTRONIC, PLC (2020) 198
12.1.8 KARL STORZ SE & CO. KG 201
TABLE 136 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW 201
12.1.9 COOK MEDICAL 204
TABLE 137 COOK MEDICAL: BUSINESS OVERVIEW 204
12.1.10 HOYA CORPORATION 206
TABLE 138 HOYA CORPORATION: BUSINESS OVERVIEW 206
FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2020) 207
12.1.11 B. BRAUN MELSUNGEN AG 209
TABLE 139 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW 209
FIGURE 47 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020) 210
12.1.12 HOBBS MEDICAL, INC. 212
TABLE 140 HOBBS MEDICAL, INC.: BUSINESS OVERVIEW 212
12.1.13 STERIS PLC 213
FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2020) 213
TABLE 141 STERIS PLC: BUSINESS OVERVIEW 214
12.1.14 MERIT MEDICAL SYSTEMS, INC. 216
TABLE 142 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 216
FIGURE 49 COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020) 217
12.1.15 TELEMED SYSTEMS, INC. 219
TABLE 143 TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW 219
12.1.16 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD. 220
TABLE 144 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW 220
12.1.17 MEDI-GLOBE GMBH 222
TABLE 145 MEDI-GLOBE GMBH: BUSINESS OVERVIEW 222
12.1.18 TAEWOONG MEDICAL CO., LTD. 223
TABLE 146 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW 223
12.1.19 HUGER MEDICAL INSTRUMENT CO., LTD. 224
TABLE 147 HUGER MEDICAL INSTRUMENT CO., LTD..: BUSINESS OVERVIEW 224
12.1.20 INTROMEDIC CO., LTD. 225
TABLE 148 INTROMEDIC CO., LTD.: BUSINESS OVERVIEW 225
FIGURE 50 COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020) 225
12.1.21 SONOSCAPE MEDICAL CORP. 227
TABLE 149 SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW 227
FIGURE 51 COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020) 227
12.2 OTHER PLAYERS 228
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies.
13 APPENDIX 230
13.1 DISCUSSION GUIDE 230
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 234
13.3 AVAILABLE CUSTOMIZATIONS 236
13.4 RELATED REPORTS 236
13.5 AUTHOR DETAILS 237



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 内視鏡的逆行性胆管膵管造影/ERCPの世界市場予測(~2026):製品別、処置別、エンドユーザー別(Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) - Global Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆